Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

Monica Crugnola, Fausto Castagnetti, Massimo Breccia, Dario Ferrero, Malgorzata Monika Trawinska, Elisabetta Abruzzese, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Massimiliano Bonifacio, Carmen Fava, Alessandra Iurlo, Cristina Bucelli, Giovanna Mansueto, Antonella Gozzini, Franca Falzetti, Enrico Montefusco, Elena Crisà, Gabriele GugliottaSabina Russo, Michele Cedrone, Antonella RussoRossi, Patrizia Pregno, Alessandro Isidori, Endri Mauro, Romano Atelda, Gianfranco Giglio, Francesca Celesti, Federica Sorà, Sergio Storti, Adam D'Addosio, Sara Galimberti, Ester Orlandi, Elisabetta Calistri, Monica Bocchia, Francesco Cavazzini, Giovanna Rege Cambrin, Nicola Orofino, Luigiana Luciano, Nicola Sgherza, Gianantonio Rosti, Roberto Latagliata, Isabella Capodanno

Research output: Contribution to journalArticle

Abstract

Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects.

Original languageEnglish
Pages (from-to)2329-2338
Number of pages10
JournalAnnals of Hematology
Volume98
Issue number10
DOIs
Publication statusPublished - Oct 2019

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Cytogenetics
Disease-Free Survival
Disease Progression
Comorbidity
Databases
Physicians

Keywords

  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate/administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
  • Male
  • Survival Rate
  • Time Factors

Cite this

Crugnola, M., Castagnetti, F., Breccia, M., Ferrero, D., Trawinska, M. M., Abruzzese, E., ... Capodanno, I. (2019). Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology, 98(10), 2329-2338. https://doi.org/10.1007/s00277-019-03767-y

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. / Crugnola, Monica; Castagnetti, Fausto; Breccia, Massimo; Ferrero, Dario; Trawinska, Malgorzata Monika; Abruzzese, Elisabetta; Annunziata, Mario; Stagno, Fabio; Tiribelli, Mario; Binotto, Gianni; Bonifacio, Massimiliano; Fava, Carmen; Iurlo, Alessandra; Bucelli, Cristina; Mansueto, Giovanna; Gozzini, Antonella; Falzetti, Franca; Montefusco, Enrico; Crisà, Elena; Gugliotta, Gabriele; Russo, Sabina; Cedrone, Michele; RussoRossi, Antonella; Pregno, Patrizia; Isidori, Alessandro; Mauro, Endri; Atelda, Romano; Giglio, Gianfranco; Celesti, Francesca; Sorà, Federica; Storti, Sergio; D'Addosio, Adam; Galimberti, Sara; Orlandi, Ester; Calistri, Elisabetta; Bocchia, Monica; Cavazzini, Francesco; Rege Cambrin, Giovanna; Orofino, Nicola; Luciano, Luigiana; Sgherza, Nicola; Rosti, Gianantonio; Latagliata, Roberto; Capodanno, Isabella.

In: Annals of Hematology, Vol. 98, No. 10, 10.2019, p. 2329-2338.

Research output: Contribution to journalArticle

Crugnola, M, Castagnetti, F, Breccia, M, Ferrero, D, Trawinska, MM, Abruzzese, E, Annunziata, M, Stagno, F, Tiribelli, M, Binotto, G, Bonifacio, M, Fava, C, Iurlo, A, Bucelli, C, Mansueto, G, Gozzini, A, Falzetti, F, Montefusco, E, Crisà, E, Gugliotta, G, Russo, S, Cedrone, M, RussoRossi, A, Pregno, P, Isidori, A, Mauro, E, Atelda, R, Giglio, G, Celesti, F, Sorà, F, Storti, S, D'Addosio, A, Galimberti, S, Orlandi, E, Calistri, E, Bocchia, M, Cavazzini, F, Rege Cambrin, G, Orofino, N, Luciano, L, Sgherza, N, Rosti, G, Latagliata, R & Capodanno, I 2019, 'Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline', Annals of Hematology, vol. 98, no. 10, pp. 2329-2338. https://doi.org/10.1007/s00277-019-03767-y
Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E et al. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology. 2019 Oct;98(10):2329-2338. https://doi.org/10.1007/s00277-019-03767-y
Crugnola, Monica ; Castagnetti, Fausto ; Breccia, Massimo ; Ferrero, Dario ; Trawinska, Malgorzata Monika ; Abruzzese, Elisabetta ; Annunziata, Mario ; Stagno, Fabio ; Tiribelli, Mario ; Binotto, Gianni ; Bonifacio, Massimiliano ; Fava, Carmen ; Iurlo, Alessandra ; Bucelli, Cristina ; Mansueto, Giovanna ; Gozzini, Antonella ; Falzetti, Franca ; Montefusco, Enrico ; Crisà, Elena ; Gugliotta, Gabriele ; Russo, Sabina ; Cedrone, Michele ; RussoRossi, Antonella ; Pregno, Patrizia ; Isidori, Alessandro ; Mauro, Endri ; Atelda, Romano ; Giglio, Gianfranco ; Celesti, Francesca ; Sorà, Federica ; Storti, Sergio ; D'Addosio, Adam ; Galimberti, Sara ; Orlandi, Ester ; Calistri, Elisabetta ; Bocchia, Monica ; Cavazzini, Francesco ; Rege Cambrin, Giovanna ; Orofino, Nicola ; Luciano, Luigiana ; Sgherza, Nicola ; Rosti, Gianantonio ; Latagliata, Roberto ; Capodanno, Isabella. / Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. In: Annals of Hematology. 2019 ; Vol. 98, No. 10. pp. 2329-2338.
@article{7de1928ebd1b4b049b21a4bb94caf87d,
title = "Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline",
abstract = "Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56{\%} of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8{\%}) and 184 (69.9{\%}) patients, respectively. In 148 cases (56.2{\%}), a major molecular response was observed, which was deep in 63 cases (24{\%}). A blastic phase occurred in 11 patients (4.2{\%}). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5{\%}) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5{\%} and 45.2{\%} in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7{\%} and 61.6{\%} in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects.",
keywords = "Aged, Aged, 80 and over, Disease-Free Survival, Female, Follow-Up Studies, Humans, Imatinib Mesylate/administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Male, Survival Rate, Time Factors",
author = "Monica Crugnola and Fausto Castagnetti and Massimo Breccia and Dario Ferrero and Trawinska, {Malgorzata Monika} and Elisabetta Abruzzese and Mario Annunziata and Fabio Stagno and Mario Tiribelli and Gianni Binotto and Massimiliano Bonifacio and Carmen Fava and Alessandra Iurlo and Cristina Bucelli and Giovanna Mansueto and Antonella Gozzini and Franca Falzetti and Enrico Montefusco and Elena Cris{\`a} and Gabriele Gugliotta and Sabina Russo and Michele Cedrone and Antonella RussoRossi and Patrizia Pregno and Alessandro Isidori and Endri Mauro and Romano Atelda and Gianfranco Giglio and Francesca Celesti and Federica Sor{\`a} and Sergio Storti and Adam D'Addosio and Sara Galimberti and Ester Orlandi and Elisabetta Calistri and Monica Bocchia and Francesco Cavazzini and {Rege Cambrin}, Giovanna and Nicola Orofino and Luigiana Luciano and Nicola Sgherza and Gianantonio Rosti and Roberto Latagliata and Isabella Capodanno",
year = "2019",
month = "10",
doi = "10.1007/s00277-019-03767-y",
language = "English",
volume = "98",
pages = "2329--2338",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

AU - Crugnola, Monica

AU - Castagnetti, Fausto

AU - Breccia, Massimo

AU - Ferrero, Dario

AU - Trawinska, Malgorzata Monika

AU - Abruzzese, Elisabetta

AU - Annunziata, Mario

AU - Stagno, Fabio

AU - Tiribelli, Mario

AU - Binotto, Gianni

AU - Bonifacio, Massimiliano

AU - Fava, Carmen

AU - Iurlo, Alessandra

AU - Bucelli, Cristina

AU - Mansueto, Giovanna

AU - Gozzini, Antonella

AU - Falzetti, Franca

AU - Montefusco, Enrico

AU - Crisà, Elena

AU - Gugliotta, Gabriele

AU - Russo, Sabina

AU - Cedrone, Michele

AU - RussoRossi, Antonella

AU - Pregno, Patrizia

AU - Isidori, Alessandro

AU - Mauro, Endri

AU - Atelda, Romano

AU - Giglio, Gianfranco

AU - Celesti, Francesca

AU - Sorà, Federica

AU - Storti, Sergio

AU - D'Addosio, Adam

AU - Galimberti, Sara

AU - Orlandi, Ester

AU - Calistri, Elisabetta

AU - Bocchia, Monica

AU - Cavazzini, Francesco

AU - Rege Cambrin, Giovanna

AU - Orofino, Nicola

AU - Luciano, Luigiana

AU - Sgherza, Nicola

AU - Rosti, Gianantonio

AU - Latagliata, Roberto

AU - Capodanno, Isabella

PY - 2019/10

Y1 - 2019/10

N2 - Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects.

AB - Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects.

KW - Aged

KW - Aged, 80 and over

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Imatinib Mesylate/administration & dosage

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy

KW - Male

KW - Survival Rate

KW - Time Factors

U2 - 10.1007/s00277-019-03767-y

DO - 10.1007/s00277-019-03767-y

M3 - Article

C2 - 31392461

VL - 98

SP - 2329

EP - 2338

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 10

ER -